Loading
companiesCompany
Protagonist Therapeutics
Protagonist is a California peptide company whose hepcidin mimetic rusfertide controls the excess red cell production of polycythaemia vera without repeated phlebotomy, with positive phase 3 VERIFY results in 2025 and a partnership with Takeda.
Also called: Protagonist Therapeutics, Inc.Protagonist
Overview
Protagonist Therapeutics, listed on Nasdaq, designs peptide medicines. Rusfertide, an injectable mimetic of the iron hormone hepcidin, restricts iron available for red cell production and in the phase 3 VERIFY trial reduced the need for phlebotomy in polycythaemia vera, a chronic myeloproliferative blood cancer; Takeda licensed the drug in 2024. The company's other lead, the oral IL-23 receptor antagonist icotrokinra, is partnered with Johnson & Johnson in psoriasis. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.
Headquarters
Newark, CA, US
Scorecard
All companies#296of 1244 companies, score 14
- approved products +6
- modalities +2
- regions +1
- registry trials +5
1 approved, 0 in phase 3, 0 earlier, 0 targets, 6 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
ApprovedHepcidin mimetic peptide
Rusfertide · Mimrylo
Rusfertide is the first drug to control polycythaemia vera's excess red cells by restricting iron, sparing patients repeated blood removal.
Similar pages
- TermHepcidin
Shares VERIFY, Rusfertide.
- TermPhlebotomy (venesection)
Shares VERIFY, Rusfertide.
- IdeaHepcidin-based control as first-line treatment in low-risk polycythaemia vera
Shares VERIFY, Rusfertide.
- TrialA Study of Rusfertide in Japanese Adults With Polycythemia Vera
Shares Rusfertide, Takeda.
- TechnologyPeptide-drug & small-molecule-drug conjugates
Shares Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera, VERIFY, Rusfertide.